Literature DB >> 29377366

Matrine reduces susceptibility to postinfarct atrial fibrillation in rats due to antifibrotic properties.

Jin Ma1, Shiyu Ma2, Chunxia Yin1, Huanlin Wu1.   

Abstract

This study aimed to investigate whether matrine could prevent atrial fibrillation (AF) after myocardial infarction by reducing left atrial fibrosis, and to determine the underlying mechanisms in isolated cardiac fibroblasts (CFs). Five weeks after MI, matrine-treated rats had lower rates of AF inducibility and shorter AF duration than MI rats. Matrine improved the left atrial conduction velocity and homogeneity. Matrine decreased the fibrosis positive areas and the protein levels of type I collagen and type III collagen in the left atrium. Matrine inhibited CFs differentiation to myofibroblasts and the expression of transforming growth factor-beta 1 and matrix metalloproteinase 9. In vitro, matrine inhibited the CFs proliferation, migration, differentiation, and secretion ability. These in vitro and in vivo data demonstrated that matrine has the potential to reduce susceptibility to AF after MI due, at least in part, to reduced atrial fibrosis via inhibiting CFs proliferation, migration, differentiation, and secretion ability.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  atrial fibrillation; cardiac fibroblast; cardiac fibrosis; left atrium; matrine; myocardial infarction

Mesh:

Substances:

Year:  2018        PMID: 29377366     DOI: 10.1111/jce.13448

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  9 in total

Review 1.  Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review.

Authors:  Yingda Lin; Qiu Du; Fuming He; Ling Wu; Yuan Xu
Journal:  Drug Des Devel Ther       Date:  2022-03-01       Impact factor: 4.162

2.  Matrine promotes liver cancer cell apoptosis by inhibiting mitophagy and PINK1/Parkin pathways.

Authors:  Runjie Wei; Jian Cao; Shukun Yao
Journal:  Cell Stress Chaperones       Date:  2018-09-12       Impact factor: 3.667

3.  Danqi soft capsule prevents infarct border zone remodelling and reduces susceptibility to ventricular arrhythmias in post-myocardial infarction rats.

Authors:  Shiyu Ma; Jin Ma; Xiaoyi Mai; Xujie Zhao; Liheng Guo; Minzhou Zhang
Journal:  J Cell Mol Med       Date:  2019-06-24       Impact factor: 5.310

4.  Isoproterenol Increases Left Atrial Fibrosis and Susceptibility to Atrial Fibrillation by Inducing Atrial Ischemic Infarction in Rats.

Authors:  Shiyu Ma; Jin Ma; Qingqiang Tu; Chaoyang Zheng; Qiuxiong Chen; Weihui Lv
Journal:  Front Pharmacol       Date:  2020-04-15       Impact factor: 5.810

5.  Exogenous hydrogen sulfide reduces atrial remodeling and atrial fibrillation induced by diabetes mellitus via activation of the PI3K/Akt/eNOS pathway.

Authors:  Xiaofei Xue; Xinyu Ling; Wang Xi; Pei Wang; Jianjun Sun; Qian Yang; Jian Xiao
Journal:  Mol Med Rep       Date:  2020-06-30       Impact factor: 2.952

Review 6.  Research Progress on Natural Products' Therapeutic Effects on Atrial Fibrillation by Regulating Ion Channels.

Authors:  Jinshan He; Sicong Li; Yumeng Ding; Yujia Tong; Xuebin Li
Journal:  Cardiovasc Ther       Date:  2022-03-22       Impact factor: 3.023

7.  Matrine attenuates pathological cardiac fibrosis via RPS5/p38 in mice.

Authors:  Xin Zhang; Can Hu; Ning Zhang; Wen-Ying Wei; Ling-Li Li; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-07-21       Impact factor: 6.150

8.  Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways.

Authors:  Song-Nan Li; Jing-Rui Zhang; Lu Zhou; Hui Xi; Chang-Yi Li; Lei Zhao
Journal:  J Cardiovasc Transl Res       Date:  2021-06-01       Impact factor: 4.132

9.  Tongguan capsule-derived herb reduces susceptibility to atrial fibrillation by inhibiting left atrial fibrosis via modulating cardiac fibroblasts.

Authors:  Shiyu Ma; Jin Ma; Liheng Guo; Junqi Bai; Shuai Mao; Minzhou Zhang
Journal:  J Cell Mol Med       Date:  2018-11-19       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.